Navigation Links
Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
Date:12/7/2009

is.href );" target="_blank" title="MM-121">MM-121, a first-in-class ErbB3 antagonist, and MM-111, a bispecific antibody targeting ErbB2 and ErbB3. Both candidates are in Phase 1 development and are expected to enter Phase 2 in 2010.

Hermes was founded in 1998 by a group of leading cancer physicians and scientists at the University of California, San Francisco, to develop lipidic nano-carriers to allow for targeted delivery of small molecule drugs, including chemotherapies, with the goal of improving cancer treatment safety and efficacy. Hermes’ lead candidate, MM-398, is a nanoliposomal formulation of CPT-11 that is currently in Phase 2 trials with a partner for multiple cancer indications (under the designation of PEP02). Merrimack expects to initiate clinical development with the next Hermes product candidate, MM-302, an antibody-targeted lipidic nano-carrier for cancer therapy, in 2010. Merrimack is privately-held and based in Cambridge, Massachusetts.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease. Its first two oncology pipeline candidates, MM-121 and MM-111, are currently in clinical development. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high-throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and w
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the six ... otherwise, are expressed in Canadian dollars and presented ... Second Quarter 2014 Highlights , Announced ... acuity (VA) primary endpoint for subjects enrolled in ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Local veterinarian, ... Veterinary Hospital are seeking candidates to participate in an ... osteoarthritis. The ultimate goal of this study is ... cells into one or two arthritically affected joints can ... , Candidates for the current investigational study must ...
(Date:8/29/2014)... Three Lawrence Livermore researchers have received ... R&D Award for their research in producing ... , Shared with collaborators from the National Renewable ... Las Vegas (UNLV), the award recognizes the team ... production and corrosion processes. , These models have ...
(Date:8/29/2014)... 2014 Due to a misstatement posted by ... Adult Stem Cell Technology Center, LLC ( ASCTC ) was ... therapy research that might benefit ALS patients. Because of ... stem cell technologies and therapeutic applications, FRC listed ASCTC as ... donors who wish not to support research that requires ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Livermore Team Awarded for Hydrogen Production Research 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... Make way for the real nanopod and make room ... with the U.S. Department of Energys Lawrence Berkeley National ... Berkeley have created the first fully functional radio from ... orders of magnitude the smallest radio ever made. , ...
... Senomyx, Inc. (Nasdaq:,SNMX), a leading company focused on ... ingredients for the packaged food and,beverage industry, announced ... Foods Global, Inc. will conclude on December 9,2007, ... term of the existing,agreement. The conclusion of this ...
... Oct. 31 Align,Technology, Inc. (Nasdaq: ALGN ... straightening teeth without wires or brackets, has been ... Silicon Valley, a,ranking of the fastest growing technology, ... by Deloitte & Touche USA LLP, one of,the ...
Cached Biology Technology:Make way for the real nanopod 2Make way for the real nanopod 3Make way for the real nanopod 4Senomyx Announces Conclusion of Discovery and Development Collaboration With Kraft Foods Global, Inc. 2Senomyx Announces Conclusion of Discovery and Development Collaboration With Kraft Foods Global, Inc. 3Align Technology, Inc. Ranked 23rd in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies 2Align Technology, Inc. Ranked 23rd in Deloitte's Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies 3
(Date:8/28/2014)... mobile app called TX Invasives is now available from ... of Texas at Austin for identifying harmful non-native plant, ... species in the United States cause about $137 billion ... agricultural crops, clog waterways, kill native plants and more. ... app for reporting where invasive species occur, we,re more ...
(Date:8/28/2014)... to announce the selection of Dr. Fred Baxendale as ... those who have served ESA for at least 20 ... Society that has reached an extraordinary level. Candidates for ... and then voted on by the ESA membership. Dr. ... Entomology 2014, ESA,s Annual Meeting in Portland, Oregon this ...
(Date:8/28/2014)... bacterial culprits that may drive inflammatory bowel diseases (IBD) ... own intestinal immune responses as a guide. , The ... Cell . , Trillions of bacteria exist within the ... the development and progression of IBD. Yet it,s thought ... a person,s susceptibility to IBD and its potential severity. ...
Breaking Biology News(10 mins):Mobile app makes ID of harmful plants, insects in Texas a snap 2Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Yale study identifies possible bacterial drivers of IBD 2
... processing fluidsIn an important advance toward the large-scale ... University have developed a new method of replacing ... with cheaper oils that are commonplace at industrial ... under the auspices of the Center for Biological ...
... conducted by a biologist at the University of California, San ... Animal Behaviour found that females of the species Uca crenulata ... their burrows before finally deciding on a mate. , “As ... sampling nearly as many candidates as the California fiddler crab,?said ...
... stem cells taken from bone marrow are the "shooting stars" ... the cells might be able to pass through the blood ... seen as the potential key to the treatment of certain ... University Clinic has produced some sobering findings: although the cells ...
Cached Biology News:The right drug at the right time 2The right drug at the right time 3Biologist Discovers What May Be World’s ‘Pickiest?Mates 2Biologist Discovers What May Be World’s ‘Pickiest?Mates 3Research casts doubt on circulating stem cells 2Research casts doubt on circulating stem cells 3
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... it easy to supply microplates, deepwells, and ... operator convenience in mind, iLink incorporates multiple ... use. The iLink software is the key ... sub-assays, that can be copied and installed ...
No-Weigh Dithiothreitol (DTT) ,7.7 mg DTT/Tube x 48 tubes...
This kit is designed to select cells labeled with phycoerythrin- (PE-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: